Tethys Bioscience Buys Lipomics | GenomeWeb
NEW YORK (GenomeWeb News) – Diagnostics developer Tethys Bioscience said today that it has bought Lipomics Technologies, a metabolite-profiling firm, for an undisclosed sum.
 
Tethys, which earlier this year began selling a test for diabetes risk, said the acquisition will help it to develop new tests to predict the likelihood of developing chronic diseases. Currently, Emeryville, Calif.-based Tethys is developing a test to predict the likelihood that a person will experience osteoporotic bone fracture or a major cardiac event.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.